Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Novo said the trial suggests the drug is safe and has a similar side effect ... potentially worth as much as $100 billion or ...
Ozempic Maker’s New Weight Loss Pill Beats Wegovy In Early Trial — What To Know About Novo Nordisk’s Amycretin
$100 billion. That’s how much some analysts believe the obesity drug market will be worth by the end of the decade. Some ...
Novo shares climb on early data for dual-acting obesity drug
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Seeking Alpha8d
Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss
Novo’s (NVO) head of drug development. Having completed the trial and given its promising results, the company expects to advance subcutaneously delivered amycretin further in clinical ...
NBC Los Angeles8d
Novo Nordisk shares pop on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.